Google
PFE 株価分析 — PFIZER INC (Healthcare >> Drug Manufacturers - General)
PFE に関するよくある質問
PFEのPER（株価収益率）は？
PFIZER INC（PFE）は現在PER 15.68倍で取引されています。
PFEのROE（自己資本利益率）は？
PFIZER INCのROEは8.31%です。
PFEの配当利回りは？
PFIZER INCの配当利回りは6.84%です。
PFEの品質スコア（Quality Score）は？
当社のAIはPFEの総合財務品質を100点中77点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
PFEは今が買い時ですか？
当社AIのタイミングスコアは100点中50点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
PFEはどのセクターに属しますか？
PFIZER INCはHealthcare >> Drug Manufacturers - Generalセクターに分類されます（NYSE市場）
PFE AI Analysis Summary
Our AI summary for PFE: PFIZER INC (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 15.68, ROE of 8.31%, a dividend yield of 6.84%. Its financial Quality Score stands at 77/100 — mid-range fundamentals relative to the market. The AI Timing Score is 50/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 25.01
Price
0.10
(0.40%)
Day Change
|
|
|---|
PFE, ファンダメンタルスコアはgood ( ファンダメンタル = 77) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
ROEが低い
ROAがROEに比べて低い
NPMが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is good , ...
| Deepscope 分析 |
|
54% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
1487
|
| Magic Formula Rank by ROE |
1487
|
| Magic Formula Rank by ROIC |
1821
|
| Price | 25.01 |
| PBV / Sector |
1.59 / 2.68
GOOD
|
| Earning Per Share | 1.31 |
| PE / Sector |
15.68 / 27.65
|
| PEG or PE/Growth / Sector |
0.26 / 0.28
GREAT
|
| Average 1M Daily Value |
842.80 M
|
| Average 1W Daily Value |
874.63 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
72% |
| 配当 |
|
100% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:19 |
| Symbol | PFE |
| Name | PFIZER INC |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 5,699.44 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 143,341.03 / 256,404.20 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 66 Hudson Boulevard East, New York, NY, United States, 10001-2192
Phone: 212 733 2323
Website: https://www.pfizer.com
Employees: 75,000
Description: Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
